세계의 휴미라 바이오시밀러 시장 : 제품 유형별, 적응증별, 유통 채널별, 환자 연령별, 지역별

Humira Biosimilar Market, By Product Type, By Indication, By Distribution Channel, By Patient Age, By Geography

US $ 4,500 ￦ 6,258,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,000 ￦ 9,735,000

PDF (Multi User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,908,000

PDF (Enterprise User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 휴미라 바이오시밀러 시장은 2025년 15억 4,050만 달러로 추정되고, 2032년까지 77억 2,400만 달러에 이를 것으로 예측되묘, 2025년부터 2032년까지 CAGR 25.9%로 추이할 것으로 예측되고 있습니다.

보고 범위		보고서 세부정보
기준연도	2024년	2025년 시장 규모	15억 4,050만 달러
실적 데이터	2020-2024년	예측 기간	2025-2032년
예측 기간: 2025-2032년 CAGR	25.90%	2032년 금액 예측	77억 2,400만 달러

휴미라는 건선과 류마티스 관절염과 같은 자가면역 질환을 치료하는 데 사용되는 생물학적 제제이며, 세계에서 가장 인기 있는 생물학적 제제입니다. 바이오시밀러 의약품은 보다 경제적인 치료 옵션을 제공함으로써 비용을 낮추고 필수적인 의약품에 대한 환자의 접근을 개선하는 데 도움이 됩니다. 경쟁은 가격을 낮추고 환자의 접근성을 향상시키고 궁극적으로 건강 관리 결과를 향상시킵니다.

시장 역학

특허 부족, 비용 절감, 자가면역 질환의 유병률 증가, 양호한 규제 환경은 예측 기간 동안 세계 휴미라 바이오시밀러 시장의 성장을 가속할 것으로 예상되는 주요 요인입니다.

예를 들어, 북미에서는 복수의 휴미라 바이오시밀러가 승인 및 도입되고 있어 바이오시밀러의 채용 시장을 리드하고 있습니다.

그러나 복잡한 규제 과정, 지적 재산 및 특허에 관한 소송, 의사와 환자의 의식 등이 예측 기간 동안 세계 뇌 혈관 촬영 시장의 성장을 방해할 것으로 예측됩니다.

본 조사의 주요 특징

• 본 보고서에서는 세계의 휴미라 바이오시밀러 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간 2025-2032년 시장 규모와 CAGR을 제공합니다.
• 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
• 또 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역에 의한 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
• 본 보고서에서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 파라미터를 바탕으로 세계의 휴미라 바이오시밀러 시장의 주요 기업 프로파일을 제공합니다.
• 본 보고서로부터 통찰에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 출시, 유형, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
• 휴미라 바이오시밀러 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 산업의 다양한 이해 관계자에 대응하고 있습니다.
• 이해관계자는 세계의 휴미라 바이오시밀러 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map (COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 특허 유효기간
  • 비용 절감
  • 자가면역질환의 유병률 증가
  • 바람직한 규제 환경
• 시장 성장 억제요인
• 시장 기회
• 규제 시나리오
• 제품 출시/승인
• PEST 분석
• Porter's Five Forces 분석
• 합병, 인수, 콜라보레이션

제4장 세계의 휴미라 바이오시밀러 시장 - 코로나 바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측의 분석
• 경제에 미치는 영향

제5장 세계의 휴미라 바이오시밀러 시장 : 제품 유형별, 2020-2032년

• 소개
• 바이오시밀러 휴미라(아달리무맙)
• 호환성 바이오시밀러 휴미라

제6장 세계의 휴미라 바이오시밀러 시장 : 적응증별, 2020-2032년

• 소개
• 류마티스 관절
• 건선
• 크론병
• 궤양성 대장염
• 강직성 척추염
• 청소년 특발성 관절염
• 기타 자가면역질환

제7장 세계의 휴미라 바이오시밀러 시장 : 환자 연령별, 2020-2032년

• 소개
• 성인 환자
• 소아 환자
• 노인 환자

제8장 세계의 휴미라 바이오시밀러 시장 : 유통 채널별, 2020-2032년

• 소개
• 병원 약국
• 소매 약국
• 온라인 약국

제9장 세계의 휴미라 바이오시밀러 시장 : 지역별, 2020-2032년

• 소개
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 이탈리아
  • 프랑스
  • 스페인
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • ASEAN 국가
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
• 중동
  • GCC 국가
  • 이스라엘
  • 기타 중동
• 아프리카
  • 북아프리카
  • 중앙 아프리카
  • 남아프리카

제10장 경쟁 구도

• 기업 프로파일
  • Amgen Inc.
  • Samsung Bioepis Co.
  • Sandoz International GmbH(Novartis AG)
  • Mylan NV
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Fresenius Kabi AG
  • Coherus BioSciences
  • Biogen Inc
  • AbbVie Inc
  • Celltrion Inc.
  • Rani Therapeutics Holdings, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co
  • Viatris Inc.
  • Alvotech
  • Analysts'Views

제11장 섹션

• 참고문헌
• 조사 방법
• 출판사에 대해

JHS

영문 목차

영문목차

Humira Biosimilar Market is estimated to be valued at USD 1,540.5 Mn in 2025 and is expected to reach USD 7,724.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 25.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 1,540.5 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	25.90%	2032 Value Projection:	USD 7,724.0 Mn

Humira is a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis and is the most popular biologic medication in the world. Following the expiration of patent protection for humira in some regions, biosimilars are highly similar copies of biologic medications in terms of safety, efficacy, and quality. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options. Biosimilars have been proven to be just as effective and safe as the original biologic medications, making them a viable alternative for patients with conditions like psoriasis and rheumatoid arthritis. Additionally, the availability of biosimilars promotes innovation in the pharmaceutical industry, as it encourages manufacturers to develop more affordable treatment options without compromising quality. This competition in the market can drive down prices and increase accessibility for patients, ultimately leading to improved healthcare outcomes. Furthermore, the introduction of biosimilars can also enhance patient choice and autonomy, allowing them to select the most suitable and cost-effective treatment for their specific needs.

Market Dynamics

Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment is major factors expected to drive growth of the global humira biosimilar market during the forecast period.

For instance, the market for multiple humira biosimilars has been approved and introduced in North America, which has led the way in the adoption of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.

However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper the growth of the global cerebral angiography market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global humira biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global humira biosimilar market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Rani Therapeutics Holdings, Inc., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Viatris Inc., and Alvotech.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market

Humira Biosimilar Market Detailed Segmentation:

• By Product Type:
  • Biosimilar Humira (Adalimumab)
  • Interchangeable Biosimilar Humira
• By Indication:
  • Rheumatoid Arthritis
  • Psoriasis
  • Crohn's Disease
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Other Autoimmune Conditions
• By Patient Age:
  • Adult Patients
  • Pediatric Patients
  • Geriatric Patients
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles:
  • Amgen
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH (Novartis AG)
  • Mylan N.V.
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Fresenius Kabi AG
  • Coherus BioSciences, Inc.
  • Biogen Inc.
  • AbbVie Inc.
  • Celltrion Inc.
  • Rani Therapeutics Holdings, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co., Inc.
  • Viatris Inc.
  • Alvotech

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Patient Age
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Patent expiration
  • Cost savings
  • Increasing prevalence of autoimmune diseases
  • Favorable regulatory environment
• Market Restraints
• Market Opportunity
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers Acquisitions, and Collaborations

4. Global Humira Biosimilar Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Humira Biosimilar Market, By Product Type, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Biosimilar Humira (Adalimumab)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Interchangeable Biosimilar Humira
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global Humira Biosimilar Market, By Indication, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Rheumatoid Arthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Psoriasis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Crohn's disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Ulcerative Colitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Ankylosing Spondylitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Juvenile Idiopathic Arthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Other Autoimmune Conditions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Humira Biosimilar Market, By Patient Age, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adult Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Pediatric Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Geriatric Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global Humira Biosimilar Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

9. Global Humira Biosimilar Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/ Region, 2020-2032, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Samsung Bioepis Co.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sandoz International GmbH (Novartis AG)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim International GmbH
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Fresenius Kabi AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Coherus BioSciences
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Biogen Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AbbVie Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Celltrion Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Rani Therapeutics Holdings, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Viatris Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Alvotech
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analysts' Views

11. Section

• References
• Research Methodology
• About us

관련자료